Aktienanalyse zu Eikon Therapeutics Inc (EIKN)EIKNEikon Therapeutics Inc

Eikon Therapeutics, Inc. is a late-stage clinical biopharmaceutical company advancing a pipeline of potential therapies for patients with unmet medical needs. The Company has clinical programs at various stages of development, and active discovery efforts in oncology and neurologic disease. Its pipeline includes EIK100, EIK1003, EIK1004, EIK1005, EIK1006, and the ARv7 Program. EIK1001 is a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses. EIK1003 and EIK1004 are selective PARP1 inhibitors. These product candidates are designed to inhibit PARP1 while sparing PARP2, thereby promoting tumor regression by targeting the DNA damage response of cancer cells. EIK1005 is designed to inhibit the WRN helicase and is our first internally developed program to advance into clinical studies. EIK1006 is being investigated as a potential next-generation AR antagonist with activity against multiple clinically emergent variants of AR. It operates in the Healthcare sector.

Eikon Therapeutics is not a good buy right now due to its significant financial losses and negative momentum. The current price is $7.26, with a year-to-date change of -59.67%. The stock has an RSI of 39.195, indicating it is nearing oversold territory but still lacks bullish momentum. The forward P/E ratio is 0, reflecting uncertainty about future earnings, and the most recent earnings report showed a loss of -1.63 per share, slightly worse than the estimate of -1.61. The main risk is the continued negative net income, which totaled -88,409,000 in Q2 2026, indicating ongoing financial struggles.